6/29/23, 11:45 PM SPARCL Pathway Feedback Search Clinical Topics Home Studies SPARCL SPARCL Disease Disease Disease Acute ischemic stroke Dyslipidemia Transient Trial question What is the role of atorvastatin in patients with recent stroke or TIA and without known coronary heart disease? Study design Multi-center Double blinded RCT Population Characteristics of study participants 40.0% female N = 4731 60.0% male 4731 patients (1908 female, 2823 male) Inclusion criteria: patients with recent stroke or TIA within one to six months, had low-density lipoprotein cholesterol levels of 100 to 190 mg/dL and without known coronary heart disease Key exclusion criteria: AF, other cardiac sources of embolism, and subarachnoid hemorrhage Interventions N=2365 atorvastatin (80 mg/day) N=2366 placebo (matching placebo every day) Primary outcome Fatal or nonfatal stroke https://web.pathway.md/studies/recFONtvShWmHsfq1 1/2 6/29/23, 11:45 PM SPARCL Pathway 13.1 % 13.1 11.2 9.8 % 6.5 % Significant decrease 3.3 % NNT = 53 0.0 % Atorvastatin Placebo Significant decrease in fatal or nonfatal stroke (11.2% vs. 13.1%; HR 0.84, 95% CI 0.71 to 0.99) Secondary outcomes Significant decrease in major cardiovascular events (14.1% vs. 17.2%; HR 0.8, 95% CI 0.69 to 0.92) No significant difference in death from any cause (9.1% vs. 8.9%; HR 1, 95% CI 0.82 to 1.21) Significant decrease in strokes or TIA (15.9% vs. 20.1%; HR 0.77, 95% CI 0.67 to 0.88) Safety outcomes No significant difference in serious adverse events. Significant differences in liver enzymes elevation (2.2% vs. 0.5, p < 0.001). Conclusion In patients with recent stroke or TIA within one to six months, had low-density lipoprotein cholesterol levels of 100 to 190 mg/dL and without known coronary heart disease, atorvastatin was superior to placebo with respect to fatal or nonfatal stroke. Reference Amarenco P, Bogousslavsky J, Callahan A rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. Open reference URL https://web.pathway.md/studies/recFONtvShWmHsfq1 2/2